PCI Biotech - Fundamentale forhold (PCIB)

[TekBot]

PCI Biotech Holding ASA is placed in Recovery Box

With reference to the announcement from PCI Biotech Holding ASA on 29.01.2026, Euronext Oslo Børs has decided to place the company in Recovery Box.

Recovery Box is a special compartment where Euronext Oslo Børs can place securities when the Issuer is subject to circumstances that make pricing of the securities particularly uncertain. Recovery Box is regulated in section 2.9.2 of Euronext Oslo Børs Rule Book II. The relevant security will remain in the Recovery Box until the circumstances for the allocation to the Recovery Box are no longer present.
…

Vis børsmeldingen

Kilde

[polygon]

@polygon

synes det er rart at Euronext aksepterer å ha listet et selskap i mange måneder uten egenkapital, verdier eller drift, og som kun bare nettopp er en notering

[TekBot]

OSLO BØRS - STATUS COMPANIES PLACED IN RECOVERY BOX AND PENALTY BENCH

Currently the following companies are placed in Recovery Box:

Barramundi Group Ltd (since 09.09.2024)
…

Vis børsmeldingen

Hynion AS (since 07.01.2026)
PCI Biotech Holding ASA (since 30.01.2026)

Recovery Box is a special compartment where Euronext Oslo Børs can place securities where the Issuer is subject to circumstances that make pricing of the securities particularly uncertain. Recovery Box is regulated in section 2.9.2 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.2 of Euronext Growth Oslo Rule Book Part II. The relevant security will remain in the Recovery Box until the circumstances for the allocation to the Recovery Box are no longer present.

Currently the following companies are placed in Penalty Bench:

Solis Bond Company DAC (since 02.05.2024)
Barramundi Group Ltd. (since 03.06.2024)
Hynion AS (since 02.06.2025)
Grøntvedt AS (since 01.07.2025)

Penalty Bench is a special compartment where the securities of Issuers that fail to comply with the Rules are placed.

Penalty Bench is regulated in section 2.9.3 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.3 of Euronext Growth Oslo Rule Book Part II. Oslo Børs will remove a security from the Penalty Bench and allocate the security to the normal compartment when the issuer has corrected the violation of the Rules that was the reason for allocating the security to the Penalty Bench.

Kilde

[Buffet]

12 øre . Stemningen er ikke helt den samme her inne som back in the days.

[mukd]

Husker jeg eide på 70-80 kr

[Snoeffelen]

Plassert i skammekroken på godt norsk.

[Investor]

Hvis det er gravøl og minnestund her får jeg komme med mine ups and Downs.

Øyeblikk man husker best (positivt):

1. Utvidelse av avtalen med AZ (2019). Kursen gikk vel fra 25 til over 80 i løpet av noen uker.

Senere kom Corona og aksjen var nede i 25 igjen.

2. Da handelen ble stoppet i slutten av juni 2020 da kursen bikket ca 80,- nok en gang. Børsen sjekket med selskapet om det var noen årsak til den kraftige oppgangen som kom på volum. Vi trodde vel da kanskje det var noe i oppgangen at det ar en avtale med AZ på gang. Husker fortsatt spenningen i kroppen.

Og det motsatte; selveste D-dagen i oktober 2020, da AstraZeneca takket for seg. Tapte 950 000 den dagen .

Synd det skulle ende såpass stusselig for selskapet. Har personlig ikke eid aksjen siden desember 2021.

[Buffet]

Kan spetalen ligge snuse på selskapet nå tro? Eller er regler mye strengere nå mtp fremførbart underskudd?

[Do2Do]

@Snoeffelen

Plassert i skammekroken på godt norsk.

De kunne gjerne nevnte ved navn styret og valgkomiteen, som virkelig burde gå i skammekroken her.

[Buffet]

Fra laboratoriet til børsrakett – han gjør medisin om til «gull»

Snart 10 år siden det var morsomt å være biotekinvestor.
Ikke mange piler igjen nå til å kaste på blinken

[polygon]

@Investor

selveste D-dagen i oktober 2020, da AstraZeneca takket for seg. Tapte 950 000 den dagen .

Den egentlige D-dagen var da AZ passerte fristen som Waladay eplekjekt hadde definert til tidligere, sommeren 2020. Men det var flere tydelige tegn i form av guidinger som ikke holdt og heller ikke ble kommentert/justert i tide tidligere i 2020 og 2019 også. Og det er i ettertid helt åpenbart at den dårlige rekrutteringen til RELEASE var fordi klinikerne ikke så god effekt - vel i likhet med for Nano. Lærdommen er aldri eie et selskap der du ikke stoler 100% på ledelsen!

[TekBot]

OSLO BØRS - STATUS COMPANIES PLACED IN RECOVERY BOX AND PENALTY BENCH

Currently the following companies are placed in Recovery Box:

Barramundi Group Ltd (since 09.09.2024)
…

Vis børsmeldingen

Hynion AS (since 07.01.2026)
PCI Biotech Holding ASA (since 30.01.2026)

Recovery Box is a special compartment where Euronext Oslo Børs can place securities where the Issuer is subject to circumstances that make pricing of the securities particularly uncertain. Recovery Box is regulated in section 2.9.2 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.2 of Euronext Growth Oslo Rule Book Part II. The relevant security will remain in the Recovery Box until the circumstances for the allocation to the Recovery Box are no longer present.

Currently the following companies are placed in Penalty Bench:

Solis Bond Company DAC (since 02.05.2024)
Barramundi Group Ltd. (since 03.06.2024)
Hynion AS (since 02.06.2025)
Grøntvedt AS (since 01.07.2025)

Penalty Bench is a special compartment where the securities of Issuers that fail to comply with the Rules are placed.

Penalty Bench is regulated in section 2.9.3 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.3 of Euronext Growth Oslo Rule Book Part II. Oslo Børs will remove a security from the Penalty Bench and allocate the security to the normal compartment when the issuer has corrected the violation of the Rules that was the reason for allocating the security to the Penalty Bench.

Kilde

[TekBot]

OSLO BØRS - STATUS COMPANIES PLACED IN RECOVERY BOX AND PENALTY BENCH

Currently the following companies are placed in Recovery Box:

Barramundi Group Ltd (since 09.09.2024)
…

Vis børsmeldingen

Hynion AS (since 07.01.2026)
PCI Biotech Holding ASA (since 30.01.2026)

Recovery Box is a special compartment where Euronext Oslo Børs can place securities where the Issuer is subject to circumstances that make pricing of the securities particularly uncertain. Recovery Box is regulated in section 2.9.2 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.2 of Euronext Growth Oslo Rule Book Part II. The relevant security will remain in the Recovery Box until the circumstances for the allocation to the Recovery Box are no longer present.

Currently the following companies are placed in Penalty Bench:

Solis Bond Company DAC (since 02.05.2024)
Barramundi Group Ltd. (since 03.06.2024)
Hynion AS (since 02.06.2025)
Grøntvedt AS (since 01.07.2025)

Penalty Bench is a special compartment where the securities of Issuers that fail to comply with the Rules are placed.

Penalty Bench is regulated in section 2.9.3 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.3 of Euronext Growth Oslo Rule Book Part II. Oslo Børs will remove a security from the Penalty Bench and allocate the security to the normal compartment when the issuer has corrected the violation of the Rules that was the reason for allocating the security to the Penalty Bench.

Kilde

[TekBot]

OSLO BØRS - STATUS COMPANIES PLACED IN RECOVERY BOX AND PENALTY BENCH

Currently the following companies are placed in Recovery Box:

Hynion AS (since 07.01.2026)
…

Vis børsmeldingen

PCI Biotech Holding ASA (since 30.01.2026)

Recovery Box is a special compartment where Euronext Oslo Børs can place securities where the Issuer is subject to circumstances that make pricing of the securities particularly uncertain. Recovery Box is regulated in section 2.9.2 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.2 of Euronext Growth Oslo Rule Book Part II. The relevant security will remain in the Recovery Box until the circumstances for the allocation to the Recovery Box are no longer present.

Currently the following companies are placed in Penalty Bench:

Hynion AS (since 02.06.2025)
Grøntvedt AS (since 01.07.2025)

Penalty Bench is a special compartment where the securities of Issuers that fail to comply with the Rules are placed.

Penalty Bench is regulated in section 2.9.3 of Oslo Rule Book II (Oslo Børs and Euronext Expand) and section 3.8.3 of Euronext Growth Oslo Rule Book Part II. Oslo Børs will remove a security from the Penalty Bench and allocate the security to the normal compartment when the issuer has corrected the violation of the Rules that was the reason for allocating the security to the Penalty Bench.

Kilde

[polygon]

Put that dog to sleep!

[TekBot]

Notice of Extraordinary General Meeting, proposed company dissolution and delisting

Oslo, Norway 23 February 2026 - An extraordinary general meeting of PCI Biotech
Holding ASA (‘PCI Biotech’ or ‘Company’) will be held at the company’s office at
Oslo Cancer Cluster Innovation Park, on 16 March 2026 at 10:00am (CET).
…

Vis børsmeldingen

The proposed resolutions include company dissolution and delisting from Euronext
Oslo Børs. The Board of Directors’ proposed resolution to dissolve PCI Biotech
is made as there is no longer any operational activity in the Company, nor is it
expected that it will resume such activity or other activities. The wholly owned
subsidiary, PCI Biotech AS, has today resolved to initiate a parallel
dissolution process.

The Board of Directors’ proposed resolution to delist the shares from Euronext
Oslo Børs is made based on the non-existent operational activity and limited
asset base. It is in the view of the Board of Directors that the Company is no
longer suitable for listing on a public trading platform and should be delisted
as soon as possible.

The complete notice and proposed resolutions to the extraordinary general
meeting are attached. The notice, including all appendices, will be made
available at PCI Biotech’s corporate website www.pcibiotech.com
(http://www.pcibiotech.com).

For further information, please contact:
Ronny Skuggedal, CEO, E-mail: rs@pcibiotech.no
Office: +47 67 11 54 00 Mobile: +47 94 00 57 57

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

[h3nk1]

[Knirkefritt]

Jeg har endel PCIB-aksjer, kjøpt tilbake når alle trodde at AstraZeneca skulle gjøre oss alle til mangemillionærer. Jeg har ikke solgt dem ennå fordi jeg har ikke hatt bruk for skattefradraget for aksjetap, (står på vanlig aksjekonto) Mitt spm er hva som skjer nå når selskapet går konkurs, jeg har vel fortsatt rett til dette fradraget?

[Savepig]

Jepp!

[InfoLeecher]

Men kan vel bli stående “evig” uoppgjort på VPS kontoen.
Så når selskapet i praksis er oppløst, tror jeg du manuelt kan skrive in tapet neste skattemelding.